Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCRX NASDAQ:IONS NASDAQ:MDGL NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCRXBioCryst Pharmaceuticals$7.95-2.3%$9.54$6.01▼$11.31$1.70B1.12.99 million shs7.97 million shsIONSIonis Pharmaceuticals$43.03+0.1%$39.07$23.95▼$50.43$6.86B0.251.75 million shs2.32 million shsMDGLMadrigal Pharmaceuticals$302.17-0.1%$295.25$200.63▼$377.46$6.72B-1.02359,418 shs236,785 shsRGENRepligen$118.91+1.6%$123.39$102.96▼$182.52$6.58B1.11948,438 shs941,488 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCRXBioCryst Pharmaceuticals-2.33%-7.02%-11.86%-10.97%+9.20%IONSIonis Pharmaceuticals+0.12%+1.87%-1.28%+31.27%-13.00%MDGLMadrigal Pharmaceuticals-0.11%+1.26%+0.67%-4.22%+6.15%RGENRepligen+1.57%-2.32%-6.34%-15.97%-28.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCRXBioCryst Pharmaceuticals4.2616 of 5 stars4.52.00.04.21.51.70.6IONSIonis Pharmaceuticals4.5496 of 5 stars4.43.00.03.03.22.50.6MDGLMadrigal Pharmaceuticals4.2722 of 5 stars3.41.00.04.62.64.20.6RGENRepligen4.693 of 5 stars4.33.00.04.51.91.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCRXBioCryst Pharmaceuticals 2.90Moderate Buy$16.70110.06% UpsideIONSIonis Pharmaceuticals 2.86Moderate Buy$59.3838.01% UpsideMDGLMadrigal Pharmaceuticals 2.89Moderate Buy$420.6339.20% UpsideRGENRepligen 2.67Moderate Buy$169.4542.51% UpsideCurrent Analyst Ratings BreakdownLatest BCRX, RGEN, IONS, and MDGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/31/2025IONSIonis PharmaceuticalsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$60.00 ➝ $64.007/31/2025IONSIonis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $65.007/31/2025IONSIonis PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$55.00 ➝ $62.007/30/2025RGENRepligenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$193.00 ➝ $204.007/30/2025RGENRepligenWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$180.00 ➝ $175.007/22/2025RGENRepligenStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOverweight$160.007/8/2025RGENRepligenEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetIn-Line ➝ In-Line$140.00 ➝ $130.007/1/2025BCRXBioCryst PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $15.007/1/2025IONSIonis PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$51.00 ➝ $57.006/30/2025BCRXBioCryst PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.006/30/2025BCRXBioCryst PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$16.00 ➝ $18.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCRXBioCryst Pharmaceuticals$450.71M3.69N/AN/A($2.30) per share-3.46IONSIonis Pharmaceuticals$944.05M7.27N/AN/A$3.96 per share10.87MDGLMadrigal Pharmaceuticals$180.13M37.24N/AN/A$34.59 per share8.74RGENRepligen$673.96M9.91$3.16 per share37.68$35.21 per share3.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCRXBioCryst Pharmaceuticals-$88.88M-$0.26N/AN/A1.33-10.62%N/A-11.06%8/4/2025 (Estimated)IONSIonis Pharmaceuticals-$453.90M-$1.84N/AN/AN/A-28.25%-45.29%-8.99%N/AMDGLMadrigal Pharmaceuticals-$465.89M-$18.05N/AN/AN/A-123.38%-50.54%-37.19%8/6/2025 (Estimated)RGENRepligen-$25.51M-$0.25N/A50.392.15-2.05%4.65%3.26%N/ALatest BCRX, RGEN, IONS, and MDGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MDGLMadrigal Pharmaceuticals-$3.64N/AN/AN/A$158.94 millionN/A8/4/2025Q2 2025BCRXBioCryst Pharmaceuticals$0.02N/AN/AN/A$149.59 millionN/A7/30/2025Q2 2025IONSIonis Pharmaceuticals$0.19$0.70+$0.51$0.70$270.90 million$452.00 million7/29/2025Q2 2025RGENRepligen$0.40$0.37-$0.03$0.26$174.62 million$182.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCRXBioCryst PharmaceuticalsN/AN/AN/AN/AN/AIONSIonis PharmaceuticalsN/AN/AN/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCRXBioCryst PharmaceuticalsN/A2.932.88IONSIonis Pharmaceuticals0.992.879.62MDGLMadrigal Pharmaceuticals0.175.915.58RGENRepligen0.276.795.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCRXBioCryst Pharmaceuticals85.88%IONSIonis Pharmaceuticals93.86%MDGLMadrigal Pharmaceuticals98.50%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipBCRXBioCryst Pharmaceuticals4.80%IONSIonis Pharmaceuticals2.60%MDGLMadrigal Pharmaceuticals21.50%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCRXBioCryst Pharmaceuticals530209.25 million199.21 millionOptionableIONSIonis Pharmaceuticals1,069159.39 million155.02 millionOptionableMDGLMadrigal Pharmaceuticals9022.20 million17.43 millionOptionableRGENRepligen1,77856.18 million55.51 millionOptionableBCRX, RGEN, IONS, and MDGL HeadlinesRecent News About These CompaniesRepligen FY2026 EPS Forecast Decreased by Leerink Partnrs2 hours ago | marketbeat.comEquities Analysts Set Expectations for Repligen Q3 Earnings4 hours ago | marketbeat.comTD Asset Management Inc Has $6.51 Million Position in Repligen Corporation (NASDAQ:RGEN)August 2 at 3:07 AM | marketbeat.comBlueshift Asset Management LLC Takes $458,000 Position in Repligen Corporation (NASDAQ:RGEN)August 2 at 3:07 AM | marketbeat.comPacer Advisors Inc. Cuts Stake in Repligen Corporation (NASDAQ:RGEN)August 2 at 3:07 AM | marketbeat.comWhat is Leerink Partnrs' Forecast for Repligen Q3 Earnings?August 2 at 2:03 AM | americanbankingnews.comWilliam Blair Has Positive View of Repligen FY2025 EarningsAugust 1 at 6:02 AM | marketbeat.comQ3 Earnings Estimate for Repligen Issued By Leerink PartnrsAugust 1 at 5:41 AM | marketbeat.comXTX Topco Ltd Buys 3,295 Shares of Repligen Corporation (NASDAQ:RGEN)August 1 at 3:05 AM | marketbeat.comFY2025 EPS Estimates for Repligen Lifted by William BlairAugust 1 at 2:15 AM | americanbankingnews.comRepligen (NASDAQ:RGEN) Given New $204.00 Price Target at Royal Bank Of CanadaJuly 31 at 11:08 AM | marketbeat.comRepligen Stock Outlook: Risk Skewed To The Downside Through 2026July 31 at 11:06 AM | benzinga.comWells Fargo & Company Issues Pessimistic Forecast for Repligen (NASDAQ:RGEN) Stock PriceJuly 31 at 10:41 AM | marketbeat.comRepligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing DigitalizationJuly 31 at 7:30 AM | globenewswire.comRepligen Corporation (NASDAQ:RGEN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesJuly 31 at 2:46 AM | americanbankingnews.comRepligen Corporation (NASDAQ:RGEN) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 31 at 2:44 AM | marketbeat.comRepligen (NASDAQ:RGEN) Shares Gap Up - Time to Buy?July 30 at 12:50 PM | marketbeat.comWhy Repligen (RGEN) Stock Is Up TodayJuly 30 at 12:16 PM | msn.comRepligen (NASDAQ:RGEN) Releases Earnings Results, Misses Expectations By $0.03 EPSJuly 30 at 9:18 AM | marketbeat.comRepligen (NASDAQ:RGEN) Issues FY 2025 Earnings GuidanceJuly 30 at 8:17 AM | marketbeat.comRepligen Corporation (RGEN) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Stocks to Buy Ahead of the Upcoming Earnings SeasonBy Chris Markoch | July 11, 2025View 3 Stocks to Buy Ahead of the Upcoming Earnings SeasonPelosi Makes Big Bet on Broadcom—Here’s Why It MattersBy Gabriel Osorio-Mazilli | July 15, 2025View Pelosi Makes Big Bet on Broadcom—Here’s Why It MattersSoundHound Rises as Short Sellers Exit and AI Demand GrowsBy Thomas Hughes | July 9, 2025View SoundHound Rises as Short Sellers Exit and AI Demand GrowsAnalysts Are Upgrading These 3 Massive AI Stocks After EarningsBy Leo Miller | July 29, 2025View Analysts Are Upgrading These 3 Massive AI Stocks After EarningsBCRX, RGEN, IONS, and MDGL Company DescriptionsBioCryst Pharmaceuticals NASDAQ:BCRX$7.95 -0.19 (-2.33%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$8.06 +0.11 (+1.45%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.Ionis Pharmaceuticals NASDAQ:IONS$43.03 +0.05 (+0.12%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$42.98 -0.05 (-0.10%) As of 08/1/2025 07:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.Madrigal Pharmaceuticals NASDAQ:MDGL$302.17 -0.34 (-0.11%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$300.90 -1.28 (-0.42%) As of 08/1/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.Repligen NASDAQ:RGEN$118.91 +1.84 (+1.57%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$118.84 -0.06 (-0.05%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
